Synokem Pharmaceuticals Limited
Synokem Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions. Founded in 1988, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. With a diverse portfolio that includes formulations in therapeutic areas such as cardiology, neurology, and anti-infectives, Synokem is recognised for its commitment to innovation and quality. The company’s state-of-the-art manufacturing facilities adhere to stringent international standards, ensuring the delivery of safe and effective products. Synokem Pharmaceuticals has achieved significant milestones, including regulatory approvals from major global health authorities, solidifying its market position. With a focus on research and development, Synokem continues to expand its reach, contributing to improved healthcare outcomes worldwide.
DitchCarbon Score
How does Synokem Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Synokem Pharmaceuticals Limited's score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Synokem Pharmaceuticals Limited's reported carbon emissions
In 2023, Synokem Pharmaceuticals Limited reported significant carbon emissions, totalling approximately 65,466,000 kg CO2e across all scopes. This includes about 6,546,600 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and approximately 4,466,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. The most substantial contribution came from Scope 3 emissions, which reached about 515,791,000 kg CO2e, primarily driven by the use of sold products (approximately 324,948,330 kg CO2e) and purchased goods and services (around 134,621,451 kg CO2e). Despite these figures, Synokem Pharmaceuticals has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or SBTi (Science Based Targets initiative) commitments indicates a potential area for improvement in their sustainability strategy. Overall, while the company has provided detailed emissions data, it currently lacks a structured approach to reducing its carbon emissions, which is increasingly critical in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 65,466,000 |
| Scope 2 | 4,466,000 |
| Scope 3 | 515,791,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Synokem Pharmaceuticals Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
